Bayer outlines next steps after glyphosate ruling, shares hold gains in DAX trade

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-29, 14:23.

Bayer (DE000BAY0017) remains in focus at Xetra and Tradegate after the recent U.S. Supreme Court decision eased litigation risks around glyphosate-based herbicides, while investors now scrutinize the group’s operational and legal strategy for the coming years.

What the court decision changed

The U.S. Supreme Court recently delivered a ruling that significantly reduced the risk of further large-scale punitive damages for Bayer in the Roundup glyphosate litigation, which triggered a sharp one-day jump of roughly 17 to 20 percent in the shares according to market reports.

Following the decision, Bank of America described the verdict as a "big win" for the group’s glyphosate litigation profile and reiterated a positive medium-term view on the company’s ability to manage remaining cases, as summarized by MarketScreener.

Analysts reassess Bayer’s risk profile

In the wake of the ruling, several houses including UBS, DZ Bank and AlphaValue/Baader adjusted their valuation scenarios and commentary, with Baader Europe downgrading Bayer to Reduce while lifting its price target, arguing that much of the litigation relief is now reflected in the valuation.

UBS, by contrast, reiterated its Buy rating, pointing to the combination of lower legal tail risk and the potential for margin improvement in the crop science and pharmaceuticals divisions in the medium term, according to recent analyst notes compiled by MarketScreener.

How Bayer earns its money

Bayer generates revenue primarily through its Crop Science, Pharmaceuticals and Consumer Health divisions, with products ranging from glyphosate-based herbicides like Roundup to prescription medicines such as Xarelto and over-the-counter brands including Aspirin, Claritin and Bepanthen, according to company information.

Where the shares trade today

The Bayer shares (DE000BAY0017) trade on 2026-06-29, 13:19 on Xetra at 46.57 euros, as indicated by real-time data from finanzen.at.

Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell any financial instrument, or any other form of regulated financial service. Investors should conduct their own research and consider their individual financial situation before making investment decisions.